<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Therapeutic guidelines are progressively emerging for the <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> (APS) </plain></SENT>
<SENT sid="1" pm="."><plain>In the absence of associated <z:hpo ids='HP_0002725'>systemic lupus erythematosus</z:hpo>, i.e. in primary APS, the prevention of <z:e sem="disease" ids="C0000809" disease_type="Disease or Syndrome" abbrv="">recurrent miscarriages</z:e> is frequently achieved by a combination of <z:chebi fb="5" ids="28304">heparin</z:chebi> plus aspirin </plain></SENT>
<SENT sid="2" pm="."><plain>To date, there is no agreement about the type and the dose of <z:chebi fb="5" ids="28304">heparin</z:chebi> to use </plain></SENT>
<SENT sid="3" pm="."><plain>Steroids should not be proposed for the prevention of <z:e sem="disease" ids="C0000786" disease_type="Disease or Syndrome" abbrv="">miscarriages</z:e> in primary APS </plain></SENT>
<SENT sid="4" pm="."><plain>Long term <z:chebi fb="8" ids="10033">warfarin</z:chebi> aimed at an International Normalized Ratio (INR) of 3-3.5 is effective for secondary prevention of <z:mp ids='MP_0005048'>thrombosis</z:mp> </plain></SENT>
<SENT sid="5" pm="."><plain>However, the appropriateness of INR for <z:chebi fb="8" ids="10033">warfarin</z:chebi> monitoring has been recently questioned in the presence of a <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> </plain></SENT>
<SENT sid="6" pm="."><plain>Education plays an important role in the management of patients with APS </plain></SENT>
<SENT sid="7" pm="."><plain>Particularly, coincident risk factors for <z:mp ids='MP_0005048'>thrombosis</z:mp> have to be suppressed or controlled </plain></SENT>
</text></document>